Global Custom Market Research Reports Provider Company

phone

Aevi Genomic Medicine Inc (GNMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 40
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The companys pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network. Aevis product candidate AEVI-002, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. It collaborates with other research institutes and companies. Aevi is headquartered in Wayne, Pennsylvania, the US.

Aevi Genomic Medicine Inc (GNMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 11
Medgenics Enters into Agreement with Harvard University 12
Licensing Agreements 13
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 13
Medgenics Enters into Licensing Agreement with Stanford University 14
Aevi Genomic Medicine Amends Licensing Agreement with Childrens Hospital of Philadelphia 15
Equity Offering 16
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 16
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 17
Medgenics Raises USD20 Million in Public Offering of Shares 18
Medgenics Raises USD46 Million in Public Offering of Shares 20
Medgenics Raises USD24.2 Million in Public Offering of Shares 22
Medgenics Completes Underwriters Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 24
Medgenics Completes Private Placement Of Units For US$9.5 Million 26
Acquisition 27
Medgenics Acquires NeuroFix Therapeutics 27
Aevi Genomic Medicine Inc - Key Competitors 28
Aevi Genomic Medicine Inc - Key Employees 29
Aevi Genomic Medicine Inc - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Mar 13, 2018: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 31
Nov 02, 2017: Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results 33
Aug 09, 2017: Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results 34
May 10, 2017: Aevi Genomic Medicine Announces First Quarter 2017 Operating Results 35
May 10, 2017: Aevi Genomic Medicine Q1 net loss decreases 36
Mar 09, 2017: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 37
Corporate Communications 39
Dec 04, 2017: Aevi Genomic Medicine Announces New Appointment to its Board of Directors 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List Of Tables

List of Tables
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 11
Medgenics Enters into Agreement with Harvard University 12
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 13
Medgenics Enters into Licensing Agreement with Stanford University 14
Aevi Genomic Medicine Amends Licensing Agreement with Childrens Hospital of Philadelphia 15
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 16
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 17
Medgenics Raises USD20 Million in Public Offering of Shares 18
Medgenics Raises USD46 Million in Public Offering of Shares 20
Medgenics Raises USD24.2 Million in Public Offering of Shares 22
Medgenics Completes Underwriters Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 24
Medgenics Completes Private Placement Of Units For US$9.5 Million 26
Medgenics Acquires NeuroFix Therapeutics 27
Aevi Genomic Medicine Inc, Key Competitors 28
Aevi Genomic Medicine Inc, Key Employees 29
Aevi Genomic Medicine Inc, Subsidiaries 30

List Of Figures

List of Figures
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aevi Genomic Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 9

Physiomics plc (Physiomics) is a computational systems biology services company. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from

View Report

Pharmstandard develops, manufactures and distributes pharmaceutical products. The company offers prescription pharmaceuticals and over-the drug (OTC) pharmaceuticals. It also provides active pharmaceutical ingredients and contract manufacturing services. Pharmstandards product portfolio

View Report

Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports